Solitary Fibrous Tumors in Clinical and Molecular Contexts

Solitary fibrous tumours (SFTs) are rare mesenchymal neoplasms characterised by a wide anatomical distribution and an unpredictable clinical course. Histologically, they comprise spindle-shaped fibroblastic cells embedded within collagenous stroma and a distinctive branching vascular pattern. The pathognomonic molecular hallmark is a somatic NAB2-STAT6 gene fusion, which converts NAB2 into an aberrant transcriptional activator and drives tumourigenesis. Risk stratification integrates clinicopathological parameters—mitotic rate, tumour size, patient age and proliferation indices such as Ki-67 expression—to predict recurrence and metastatic potential. Clinically, complete surgical excision remains the standard of care for localised disease, while advanced or recurrent SFTs present therapeutic challenges. Emerging systemic approaches include antiangiogenic agents targeting VEGF signalling, immunotherapy against PD-L1, RNA-targeting strategies and novel molecular inhibitors informed by genomic profiling. Recent advances have refined diagnostic algorithms, risk models and therapeutic avenues, underscoring the global imperative to harmonise molecular insights with clinical management.

Research from Nature Portfolio

Recent studies have identified novel molecular and immunological targets within SFTs. One analysis described an integrated risk stratification model incorporating mitotic count, density of Ki-67+ and CD163+ cells, and MTOR mutation status, which outperforms previous models in predicting progression in both central nervous system and non-CNS SFT cohorts. This work also highlighted high PD-L1 expression and macrophage infiltration as potential biomarkers for combinatorial immunotherapy. Parallel research into insulin-like growth factor-2 (IGF-2) precursors revealed that unprocessed pro-IGF2(156) and the non-glycosylated form big-IGF2(104) exhibit enhanced mitogenicity and receptor affinity, suggesting a role in tumour growth and paraneoplastic hypoglycaemia. These findings illuminate new therapeutic avenues and deepen understanding of SFT biology.

Solitary Fibrous Tumors in Clinical and Molecular Contexts publication trend

The graph below shows the total number of articles in solitary fibrous tumors in clinical and molecular contexts across all publications each year (not limited to Nature Index journals).

Technical terms

Mesenchymal neoplasm: A tumour arising from connective tissue lineages such as fibroblasts and characterised by spindle-cell morphology.

NAB2-STAT6 fusion: A chromosomal rearrangement that joins NAB2 and STAT6 genes, producing an aberrant transcriptional activator central to SFT pathogenesis.

Risk stratification model: A prognostic tool combining clinical and pathological variables to predict disease progression and guide management.

Antisense oligonucleotide (ASO): A short synthetic nucleic acid designed to bind specific RNA sequences and modulate gene expression.

Pro-IGF2 prohormones: Precursor forms of insulin-like growth factor-2 that can exhibit distinct biological activities and contribute to paraneoplastic syndromes.

References

1. Comprehensive analysis reveals potential therapeutic targets and an integrated risk stratification model for solitary fibrous tumors. Nature Communications (2023).
2. Advances in the molecular biology of the solitary fibrous tumor and potential impact on clinical applications. Cancer and Metastasis Reviews (2024).
3. STAT6-targeting antisense oligonucleotides against solitary fibrous tumor. Molecular Therapy - Nucleic Acids (2024).
4. Non-glycosylated IGF2 prohormones are more mitogenic than native IGF2. Communications Biology (2023).
5. A Comprehensive Review on Solitary Fibrous Tumor: New Insights for New Horizons. Cancers (2021).
6. Novel Therapeutic Options for Solitary Fibrous Tumor: Antiangiogenic Therapy and Beyond. Cancers (2022).